Release Date: August 1, 2018 Expiration Date: July 31, 2019 (subject to change)
Continuing education credit for this activity will not be available after this date.
90 days after completion of this continuing education activity, learners will receive an invitation to complete a post-impact survey. This is designed to help measure how this material impacts practice behaviors and changes in the learners thinking and care of patients. It is anonymous and optional. It does not affect the credit earned for this activity. Overview COPD, a slowly progressive respiratory disease comprising emphysema, chronic bronchitis, and some forms of bronchiectasis,is the third leading cause of death in the United States and is projected to become the third leading cause of death worldwide by 2020. Approximately 15 million adults have a diagnosis of COPD, but the true number of individuals with COPD may be considerably higher. Treatment goals include symptom management and reduction of future risk. However, many patients with COPD are not achieving these goals due to delayed or missed diagnoses and/or suboptimal treatment. This activity will examine risk factors, strategies for the recognition and assessment of early symptoms, criteria for diagnosis, and the implementation of a comprehensive patient-centered approach to disease management. CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the educational content completely:
Video Presentations: Watch all video presentations completely.
Review all additional materials provided (handouts, posttest reviews, any other downloadable resources).
After completing all content, go to Steps to Receive Credit to complete the posttest and evaluation to receive full AANP CE/Rx credit.
If other types of credit are offered for the activity, these options will be available after completing the activity evaluation.
90-Day Post Impact Survey: Optional survey to help AANP develop additional continuing education activities.
Review evidence-based strategies for screening, diagnosis, and assessment of COPD.
Describe the most current guideline recommendations for the pharmacologic treatment of COPD, including agents discussed in the guidelines.
Describe the most current guideline recommendations for the nonpharmacologic treatment of COPD.
Recognize acute exacerbations of COPD.
Discuss strategies for promoting patient adherence to COPD therapy.
Faculty Susan J. Corbridge, PhD, APRN, FAANP Disclosure This activity was planned in accordance with AANP Accreditation Standards and Policies and was developed by the American Association of Nurse Practitioners in cooperation with MCM Education, Newtown, PA. This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Corbridge’s spouse is an employee of GlaxoSmithKline pharmaceutical company. This educational activity may contain opinions of the speakers from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Additional Information For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.
1 Contact Hour(s) of CE, 0.25 of which may be applied towards Pharmacology